Stock listing

Glaukos Corporation

Selected listing: A14VCK · LS · EUR · DE

Glaukos Corporation (Lang & Schwarz: A14VCK), Health Technology. Latest release Jul 29, 2026: Glaukos Announces Second Quarter 2026 Financial Results.

A14VCK:LSEURDEUpdated October 2, 2026

Ticker: Lang & Schwarz: A14VCK
Asset type: Stock
Sector: Health Technology
Industry: Medical Specialties
Exchange: Lang & Schwarz
Currency: EUR

About Glaukos Corporation

The company focuses on developing innovative therapies for the treatment of eye diseases, particularly glaucoma. Glaukos aims to improve patient outcomes through advanced surgical and pharmaceutical solutions.

Latest news from Glaukos Corporation

Glaukos Announces Second Quarter 2026 Financial Results

July 29, 2026

Glaukos Announces Completion of Patient Enrollment in 510(k) Pivotal Study for PRESERFLO™ MicroShunt

July 27, 2026

Glaukos to Release Second Quarter 2026 Financial Results after Market Close on July 29

July 8, 2026

Glaukos Announces Completion of Patient Enrollment in Phase 2 Study of GLK-321 for Demodex Blepharitis

June 25, 2026

Glaukos Announces First Quarter 2026 Financial Results

April 29, 2026

All Glaukos Corporation news →

Events

Replays

Glaukos Corporation (GKOS) Q2 2026 Earnings Call
Wed, Jul 29, 2026 · 04:30 PM ET
Watch
Glaukos Corporation (GKOS) Q1 2026 Earnings Call
Wed, Apr 29, 2026 · 04:30 PM ET
Watch
Glaukos Corporation (GKOS) Q4 2025 Earnings Call
Tue, Feb 17, 2026 · 04:00 PM ET
Watch

Research Glaukos Corporation

Glaukos Corporation company profile

View the public company page for Glaukos Corporation on 6ix.

Glaukos Corporation news

Read company news and market updates connected to Glaukos Corporation.

Glaukos Corporation investor events

Find investor webinars, events, and replay context for Glaukos Corporation.